Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

Eli Lilly is sharpening its competitive edge in the crowded oral SERD arena as the FDA has approved a combination of its ...

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...

Eli Lilly is marking World Alzheimer’s Day with a partnership to distribute 13,500 boxes of brain-healthy fresh produce and ...

Major drugmakers and top agencies alike earned their flowers at the annual Fierce Pharma Marketing Awards gala in ...

Following the news that longtime helmsman Paul Chaplin would be hanging up his hat at Bavarian Nordic earlier this year, the ...

Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations. The health and hygiene ...

New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, ...

A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...

BioMarin is pumping the brakes on yet another indication for its CNP analogue, Voxzogo. | The rare disease biotech announced ...